Prevention of Flares in Children with Atopic Dermatitis with Regular Use of an Emollient Containing Glycerol and Paraffin: A Randomized Controlled Study
| Autor: | Alain Delarue, George Sorin Tiplica, Eric Garrigue, Laura Malinauskienė, Franck Boralevi, Pille Konno, Andrzej Kaszuba, Markéta Saint-Aroman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Glycerol
Male medicine.medical_specialty medicine.drug_class Symptom Flare Up Dermatology Dermatitis Atopic law.invention 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Humans Medicine 030212 general & internal medicine Limited evidence Child Glucocorticoids Emollients business.industry Standard treatment Complete remission Atopic dermatitis medicine.disease Treatment Outcome Topical corticosteroid Paraffin Child Preschool Pediatrics Perinatology and Child Health Corticosteroid Female business |
| Zdroj: | Pediatric Dermatology. 34:282-289 |
| ISSN: | 0736-8046 |
| DOI: | 10.1111/pde.13113 |
| Popis: | Background/Objectives Emollients are part of the standard treatment for atopic dermatitis (AD), although there is limited evidence that regular use of emollients as management therapy reduces the frequency of flares and corticosteroid consumption. The objective of this study was to evaluate the benefit of emollient use in the management of mild to moderate AD in children by assessing the ability of two different emollients (particularly V0034CR) to prevent flares and to reduce the use of corticosteroids. Methods In this randomized, open-label study, patients with a current flare were treated with a potent topical corticosteroid. After flare resolution, patients were centrally randomized to V0034CR emollient, reference emollient, or no emollient (1:1:1 ratio) for 12 weeks. New flares were medically assessed before being treated with a moderately potent corticosteroid. Results A total of 335 children 2 to 6 years of age were randomized. At 12 weeks, the percentage of patients with one or more flares was statistically significantly lower with V0034CR (35.1%) than without emollient (67.6%; p < 0.001). Fewer patients treated with V0034CR required any corticosteroids or immunosuppressants (23.6%) than patients with no emollient (43.3%) at 12 weeks. The difference was significant at all time points (p = 0.002). Patients treated with emollients had a longer time to first flare, fewer flares, higher complete remission rates, less corticosteroid consumption, lower Investigator Global Assessment scores, and lower Scoring Atopic Dermatitis scores than those who were not. V0034CR was well tolerated, with no specific safety concerns. Conclusion Regular emollient use in children with mild to moderate AD reduces flares and corticosteroid consumption. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text